Retigabine or ezogabine is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. From Wikipedia
Research from Mount Sinai identifies potassium channels as key targets for addressing treatment-resistant depression and anhedonia, with plans for larger clinical trials underway.
